We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Science Applications' (SAIC) Q4 Earnings?
Read MoreHide Full Article
Science Applications International Corporation (SAIC - Free Report) is set to report fourth-quarter fiscal 2020 results on Mar 26.
The company’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and missed in the other, the average positive surprise being 11.7%.
In the last reported quarter, the company delivered earnings of $1.39 per share, missing the Zacks Consensus Estimate of $1.44. However, the bottom-line figure improved nearly 3% year over year. Moreover, revenues jumped 38% from the year-ago quarter to $1.6 billion but lagged the Zacks Consensus Estimate of $1.63 billion.
Science Applications International Corporation Price and Consensus
The Zacks Consensus Estimate for fiscal fourth-quarter revenues is pegged at $1.57 billion, indicating approximately 32% improvement from the year-ago reported figure. For earnings, the consensus estimate stands at $1.32, suggesting 12.8% year-over-year growth.
Let’s see how things are shaping up prior to this announcement.
Factors to Consider
Science Applications’ fiscal fourth-quarter performance is likely to have benefited from its strong product portfolio, which is aiding contract wins. The company’s capability to sustain its existing contracts, coupled with the newly-awarded ones across the customer portfolio, is likely to have been a steady tailwind.
Moreover, the integration of the Engility buyout might have driven the company’s top and bottom lines. In the last reported quarter, excluding Engility, revenues dipped 1.5%, year on year.
The acquisition of Engility is also likely to have boosted the company’s margin profile and cash flow.
Nonetheless, revenue dis-synergies due to the elimination of prime sub-duplicate revenues might have had a slight negative impact. Further, higher interest expenses are likely to have dampened the bottom line.
Furthermore, investors should be more focused on the company’s guidance rather than the quarterly results. Science Applications’ guidance for fiscal 2021 will give a proper insight about the company’s plans to combat the coronavirus crisis and stay afloat.
What Our Model Says
Our proven model does not predict an earnings beat for Science Applications this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
Science Applications currently carries a Zacks Rank of 2 and has an Earnings ESP of -0.51%.
Stocks to Consider
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat in their soon to be reported quarterly results:
Ascendis Pharma A/S (ASND - Free Report) has an Earnings ESP of +3.15% and carries a Zacks Rank of 3, at present.
Lululemon Athletica Inc. (LULU - Free Report) has an Earnings ESP of +0.42% and currently carries a Zacks Rank of 3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Shutterstock
What's in Store for Science Applications' (SAIC) Q4 Earnings?
Science Applications International Corporation (SAIC - Free Report) is set to report fourth-quarter fiscal 2020 results on Mar 26.
The company’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and missed in the other, the average positive surprise being 11.7%.
In the last reported quarter, the company delivered earnings of $1.39 per share, missing the Zacks Consensus Estimate of $1.44. However, the bottom-line figure improved nearly 3% year over year. Moreover, revenues jumped 38% from the year-ago quarter to $1.6 billion but lagged the Zacks Consensus Estimate of $1.63 billion.
Science Applications International Corporation Price and Consensus
Science Applications International Corporation price-consensus-chart | Science Applications International Corporation Quote
The Zacks Consensus Estimate for fiscal fourth-quarter revenues is pegged at $1.57 billion, indicating approximately 32% improvement from the year-ago reported figure. For earnings, the consensus estimate stands at $1.32, suggesting 12.8% year-over-year growth.
Let’s see how things are shaping up prior to this announcement.
Factors to Consider
Science Applications’ fiscal fourth-quarter performance is likely to have benefited from its strong product portfolio, which is aiding contract wins. The company’s capability to sustain its existing contracts, coupled with the newly-awarded ones across the customer portfolio, is likely to have been a steady tailwind.
Moreover, the integration of the Engility buyout might have driven the company’s top and bottom lines. In the last reported quarter, excluding Engility, revenues dipped 1.5%, year on year.
The acquisition of Engility is also likely to have boosted the company’s margin profile and cash flow.
Nonetheless, revenue dis-synergies due to the elimination of prime sub-duplicate revenues might have had a slight negative impact. Further, higher interest expenses are likely to have dampened the bottom line.
Furthermore, investors should be more focused on the company’s guidance rather than the quarterly results. Science Applications’ guidance for fiscal 2021 will give a proper insight about the company’s plans to combat the coronavirus crisis and stay afloat.
What Our Model Says
Our proven model does not predict an earnings beat for Science Applications this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
Science Applications currently carries a Zacks Rank of 2 and has an Earnings ESP of -0.51%.
Stocks to Consider
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat in their soon to be reported quarterly results:
FactSet Research Systems Inc. (FDS - Free Report) has an Earnings ESP of +0.77% and carries a Zacks Rank of 2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ascendis Pharma A/S (ASND - Free Report) has an Earnings ESP of +3.15% and carries a Zacks Rank of 3, at present.
Lululemon Athletica Inc. (LULU - Free Report) has an Earnings ESP of +0.42% and currently carries a Zacks Rank of 3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>